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 Synopsis 23 
Objectives - To compare the antibiotic susceptibility of Pseudomonas aeruginosa strains with increased 24 
efflux-pump expression in vitro and in vivo and to use these same strains to evaluate the efficacy of 25 
combinations of antibiotics with putative efflux-pump inhibitors in vivo. 26 
Methods – A collection of P. aeruginosa strains that over-express three efflux-pumps (MexAB-OprM, 27 
MexCD-OprJ, MexEF-OprN), in addition to a strain with all three Mex pumps deleted, were used. The 28 
virulence of these strains and their antibiotic susceptibility was measured in vivo using a Galleria mellonella 29 
larval infection model. The inhibitory effect of combinations of putative efflux-pump inhibitors (trimethoprim 30 
and sertraline) with antibiotics on the strain over-expressing MexAB-OprM was also measured in vitro and 31 
compared with their efficacy in vivo in terms of larval survival and bacterial burden. 32 
Results – Increased expression of the individual efflux-pumps, or deletion of all three, had no significant 33 
effect on the virulence of P. aeruginosa in vivo. Expression levels of the efflux-pumps clearly influenced 34 
antibiotic efficacy in vivo. The efficacy of levofloxacin, piperacillin and meropenem versus larvae infected 35 
with the efflux-pump mutants reflected susceptibility to the same drugs in vitro. Treatment of G. mellonella 36 
larvae infected with a strain that over-expressed MexAB-OprM with a combination of putative efflux-pump 37 
inhibitors and levofloxacin resulted in enhanced therapeutic benefit compared to the constituent 38 
monotherapies. 39 
Conclusions - This study has demonstrated the utility of using G. mellonella to screen for novel therapeutic 40 
options for MDR P. aeruginosa and has shown that antibiotic/efflux-pump inhibitor combinations should be 41 
further investigated for clinical application. 42 
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 Introduction 49 
Pseudomonas aeruginosa is a ubiquitous, opportunistic pathogen prominent in hospitalised, 50 
immunocompromised patients where it targets the urinary and respiratory tracts, kidneys and bloodstream 51 
principally via invasive fomites such as catheters and mechanical ventilators.1 Treatment of P. aeruginosa 52 
infections can be difficult due to its high intrinsic resistance, which in turn has been amplified by the rapid 53 
spread of resistance determinants and arrival of the MDR phenotype where isolates are resistant to three 54 
or more different classes of antibiotics. 55 
The over-expression of membrane-associated efflux-pumps that contribute to reduced efficacy of a number 56 
of important classes of antibiotics used against P. aeruginosa is an important contributor to resistance.2 57 
The most significant family of efflux-pumps that mediate antibiotic resistance in P. aeruginosa are those 58 
belonging to the resistance-nodulation-division (RND). Four of the twelve member RND family are strongly 59 
associated with antibiotic efflux: MexAB-OprM, MexXY-OprM, MexCD-OprJ and MexEF-OprN.3 These four 60 
pumps transport an overlapping range of antibiotic substrates, in particular the fluoroquinolones. However, 61 
MexAB-OprM is the least discriminatory, with a broad substrate range allowing extrusion of almost all 62 
classes of antibiotic, and is the most important efflux-pump mediating antibiotic resistance because it is 63 
constitutively expressed and responsible for much of the intrinsic resistance of the organism.3 Knockout of 64 
mexAB-oprM results in hyper-susceptibility to antibiotics.4 In contrast, expression of MexCD-OprJ and 65 
MexEF-OprN requires exposure to a broad range of compounds or environmental stimuli.2 MexCD-OprJ’s 66 
substrate range mirrors that of MexAB-OprM while MexEF-OprN appears the least versatile.3 Knockout of 67 
either of these two pumps does not affect antibiotic susceptibility.5 Mutations in efflux-pump regulatory 68 
genes can result in over-expression of any of these pumps and confer a multi-drug resistant phenotype. 69 
Importantly, these mutations are commonly identified in clinical isolates, for example, mutations in nalB,6 70 
nfxB7 and nfxC8 result in over-expression of MexAB-OprM, MexCD-OprJ and MexEF-OprN respectively.  71 
The role of efflux-pumps in mediating resistance to antibiotics has led to efforts to inhibit their activity as a 72 
strategy to reduce the level of antibiotic resistance. Identifying combination treatments of efflux-pump 73 
inhibitors (EPIs) with these antibiotics could result in the restoration of antibiotic activity.  74 
In two independent studies, evidence was presented that the antibiotic trimethoprim9 and the selective 75 
serotonin reuptake inhibitor sertraline10 were synergistic in combination with a range of antibiotics versus 76 
Gram-negative bacteria in vitro. Both drugs demonstrated EPI-like activity by inhibiting the efflux of dyes 77 
 from these bacteria. Using a collection of characterised P. aeruginosa strains that over-express three RND 78 
efflux pumps (MexAB-OprM, MexCD-OprJ, MexEF-OprN11), the aim of this study was to assess the efficacy 79 
of combinations of antibiotics with sertraline and trimethoprim using a Galleria mellonella infection model in 80 
vivo to determine if these combinations could represent a future treatment option for infections with P. 81 
aeruginosa strains that display an efflux-pump mediated MDR phenotype. 82 
 83 
Materials and Methods 84 
Bacteria and growth media. The strains of P. aeruginosa used in this study are shown in Table 1. Strain 85 
PAO1 and the efflux pump mutants were a kind gift of Dr. Olga Lomovskaya, Rempex Pharmaceuticals, 86 
USA. P. aeruginosa NCTC13437 was obtained from the National Collection of Type Cultures (NCTC) 87 
(http://www.phe-culturecollections.org.uk/collections/nctc.jsp ). All strains were cultured overnight in 88 
Mueller-Hinton Broth (MHB; Merck, Darmstadt, Germany) at 37ºC with shaking to prepare inocula for drug 89 
susceptibility testing in vitro and efficacy testing in vivo.  90 
Antibiotics and G. mellonella larvae. All antibiotics: ceftazidime (CFD), piperacillin (PIP), meropenem 91 
(MER), amikacin (AMK), levofloxacin (LVX) and colistin (CST) and Pseudomonas Isolation Agar (PIA) were 92 
purchased from Sigma-Aldrich Ltd (Dorset, UK). Stock solutions and sub-stocks were made using sterile 93 
deionised water. Putative efflux-pump inhibitors sertraline HCl (SER), trimethoprim (TMP) and PAβN were 94 
purchased from Sigma-Aldrich Ltd. Stock solutions of sertraline and trimethoprim were made in 50% and 95 
75% (v/v) DMSO respectively. PAβN was made in sterile deionised water. Sub-stocks of all drugs for use in 96 
experiments were made in sterile deionised water. G. mellonella larvae were purchased from UK 97 
Waxworms Ltd (Sheffield, UK). 98 
Drug susceptibility testing. This was performed exactly as previously described.13 Briefly, the MIC of each 99 
antibiotic and the putative EPIs versus P. aeruginosa strains was determined in 96-well microplates 100 
(Greiner Bio-one Ltd, Stonehouse, UK) via doubling dilution of each drug in MHB and subsequent 101 
inoculation with 1.0x106 cfu/mL of P. aeruginosa. The MIC value of combinations of antibiotics with EPIs 102 
was carried out exactly as above using 96-well microplate assays prepared via doubling dilution of each 103 
antibiotic in MHB followed by addition of a single concentration of each EPI. All three putative EPIs 104 
(trimethoprim, sertraline and PAβN) were tested in combination with levofloxacin, piperacillin and 105 
 meropenem. Each EPI was screened in combination with the antibiotics at concentrations over three orders 106 
of magnitude that were lower than the MIC values for each EPI. Microplates were incubated at 37ºC and 107 
the MIC was defined as the concentration present in the first optically clear well after 24 h. Each experiment 108 
was performed in triplicate. Fractional inhibitory concentration index (FICI) values were calculated for each 109 
combination tested,14 and synergy was defined as FICI ≤0.5. 110 
G. mellonella model of P. aeruginosa infection and determination of G. mellonella haemolymph burden. 111 
This was performed exactly as previously described.13 Unless otherwise stated, groups of larvae were 112 
infected with an inoculum of of 2.5x103 cfu/mL of P. aeruginosa cells. For experiments involving a single 113 
dose of levofloxacin (0.2, 1 or 5 mg/kg), piperacillin (10, 25 or 100 mg/kg) or meropenem (0.1, 0.25 or 0.5 114 
mg/kg), the antibiotics were administered 2 h post-infection (p.i). For experiments involving triple doses of 115 
either single drugs or dual drug combinations, 1 and 5 mg/kg levofloxacin were used for PAM1020 and 116 
PAM1032, respectively. A dose of 100 mg/kg of either trimethoprim or sertraline was used in combination 117 
with levofloxacin as pilot studies using both PAM1020 and PAM 1032 revealed this dose resulted in optimal 118 
results (data not shown). Triple doses were administered 2, 4 and 6 h p.i. Each experiment used groups 119 
containing 15 larvae and experiments were performed twice using larvae from different batches. The data 120 
from these replicate experiments were pooled to give n=30. Survival data were plotted using the Kaplan-121 
Meier method and comparisons made between groups using the log rank test. In all comparisons to the 122 
negative control it was the uninfected control (rather than the unmanipulated control) that was used. In all 123 
tests P0.05 was considered significant and Holm’s correction was always applied to account for multiple 124 
comparisons.15 125 
For haemolymph burden, groups of 30 larvae were infected with 2.5x103 cfu/mL of P. aeruginosa. As 126 
above, single drug or dual combinations were administered at either 2 h p.i. as a single dose or at 2, 4 and 127 
6 h p.i. for multiple dosing. The larvae were incubated in Petri dishes at 37ºC. At 24 h intervals, five larvae 128 
were selected at random from each treatment group and tested for haemolymph burden exactly as 129 
previously described.16 130 
Results 131 
Expression levels of efflux-pumps do not influence virulence of P. aeruginosa in G. mellonella larvae. 132 
Groups of larvae were infected with each of the four mutant strains of P. aeruginosa with altered efflux 133 
 pump expression and the isogenic parent strain (Supplementary Figure 1). With all strains tested, the heat-134 
killed P. aeruginosa inoculum (inoculation dose of 2.5x108 cfu/mL) had no significant detrimental effect on 135 
larval survival (P>0.05) indicating that infection with live bacteria is required to cause larval death. 136 
Inoculation with 25 cfu/larva of each strain resulted in 100% lethality after 24 h compared to controls sham-137 
infected with PBS. No difference in virulence between the strains was discernible. Reducing the inoculum 138 
size 10-fold to 2.5 cfu/larva allowed better discrimination of any differences in virulence between the 139 
strains. Despite some apparent differences in larval survival 48 h post-infection (p.i), after 96 h there was 140 
no significant difference (P≥0.05) in survival of larvae infected with any of the strains tested. In conclusion, 141 
alteration of efflux-pump expression had no significant effect on the virulence of P. aeruginosa in G. 142 
mellonella larvae. 143 
 144 
Antibiotic susceptibility of P. aeruginosa strains with altered expression levels of efflux-pumps is affected in 145 
vitro and this correlates with the efficacy of these antibiotics versus G. mellonella larvae infected with the 146 
same strains. In vitro susceptibility of the parent strain and four efflux-pump mutants to a range of anti-147 
Pseudomonal antibiotics is shown in Table 2. Over-expression of mexAB-oprM (PAM1032) conferred 148 
resistance to ceftazidime, piperacillin, meropenem and levofloxacin compared to the isogenic parent 149 
(PAM1020). Over-expression of mexCD-oprJ (PAM1033) and mexEF-oprN (PAM1034) conferred 150 
significant resistance to levofloxacin only. The mutant with all three efflux pumps deleted (PAM1626) 151 
displayed susceptibility to ceftazidime, piperacillin, meropenem and levofloxacin compared to the parent 152 
(PAM1020). Together, these results are consistent with many previous studies on the substrate specificity 153 
of these efflux-pumps. 2 154 
To study the effect of altered efflux pump expression on in vivo antibiotic efficacy infected larvae were 155 
treated with levofloxacin, piperacillin and meropenem as these three drugs had the largest differences in 156 
susceptibility between the mutant and parent strains in vitro (see Table 2). Larvae were infected with each 157 
strain of P. aeruginosa and the effect of a single, increasing dose of each antibiotic on survival measured 158 
(Figure 1). Treatment with 0.2 mg/kg of levofloxacin conferred no therapeutic benefit on larvae infected with 159 
any of the P. aeruginosa strains tested. Notably, a single dose of 1 mg/kg levofloxacin only induced 160 
therapeutic benefit on larvae infected with the mutant with all three efflux pumps deleted (PAM1626). 161 
Increasing the dose to 5 mg/kg levofloxacin resulted in almost complete survival of larvae infected with the 162 
 triple deletion mutant but also the parent strain (PAM1020). Notably, this highest dose of levofloxacin 163 
offered no therapeutic benefit to larvae infected with the three mutant strains that over-expressed the three 164 
efflux pumps (PAM1032, PAM1033 and PAM1034). A similar trend of antibiotic efficacy, dependent on the 165 
level of efflux-pump expression, was also observed when larvae infected with each strain were treated with 166 
increasing doses of piperacillin. Similar to treatment with levofloxacin and piperacillin, treatment with 167 
meropenem was most effective on larvae infected with the mutant with all three efflux pumps deleted 168 
(PAM1626). Treatment with 0.25 or 0.5 mg/kg meropenem proved to be efficacious to larvae infected with 169 
the parent strain (PAM1020) and the strains over-expressing mexCD-oprJ (PAM1033) or mexEF-oprN 170 
(PAM1034). Notably, over-expression of mexAB-oprM (PAM1032) abolished this efficacy. 171 
In conclusion, the expression level of efflux-pumps clearly influences antibiotic efficacy in vivo. 172 
Furthermore, the in vivo efficacy of levofloxacin, piperacillin and meropenem versus larvae infected with P. 173 
aeruginosa strains displaying altered expression of efflux-pumps reflected exactly the degree of 174 
susceptibility to the same drugs that was measured in vitro.  175 
 176 
Treatment of G. mellonella larvae infected with MDR strains of P. aeruginosa with a combination of putative 177 
efflux-pump inhibitors and levofloxacin results in enhanced therapeutic benefit compared to the constituent 178 
monotherapies. The antibiotic trimethoprim9 and the selective serotonin reuptake inhibitor sertraline10 179 
represent two clinically-approved drugs that have also been shown to be putative inhibitors of Gram-180 
negative efflux-pumps. The MICs of these two drugs and the established EPI PAβN17 are shown in 181 
Supplementary Table 1. Only the mutant with all three efflux-pumps deleted (PAM1626) displayed any 182 
substantial susceptibility, and the three strains over-expressing individual efflux pumps had a higher MIC 183 
for trimethoprim than the parent, implying that all three putative EPIs may be substrates of these Mex 184 
efflux-pumps. MIC and FICI values of the three EPIs in combination with levofloxacin, piperacillin and 185 
meropenem are shown in Table 3. Combination MICs were determined for the parent strain (PAM1020), 186 
the triple efflux-pump deletion (PAM1626) and the mutant over-expressing mexAB-oprM (PAM1032). 187 
PAM1032 was included over the mutants over-expressing mexCD-oprJ and mexEF-oprN because this 188 
strain was the most resistant to levofloxacin, piperacillin and meropenem treatment in vivo and MexAB-189 
oprM is responsible for intrinsic resistance of P. aeruginosa to many antibiotics. Combination of 190 
trimethoprim, sertraline and PAβN with levofloxacin each resulted in a reduction in the MIC of levofloxacin 191 
 versus the parent strain (PAM1020). The calculated FICI values for each of these combinations indicated 192 
synergistic inhibition (≤0.5). Synergy was also observed against the parent strain for combinations of 193 
piperacillin with trimethoprim and PAβN, and meropenem with sertraline. None of the putative EPI/antibiotic 194 
combinations showed significant synergy versus the strain with all three efflux-pumps deleted (PAM1626). 195 
In contrast to the parent strain (PAM1020), trimethoprim and sertraline did not act in synergy with the 196 
antibiotics versus the mutant over-expressing mexAB-oprM (PAM1032). Only the established efflux-pump 197 
inhibitor PAβN was synergistic in combination with all three antibiotics against this mutant.  198 
Antibiotic and EPI combinations were then investigated in the G. mellonella infection model for in vivo 199 
efficacy. Irrespective of the P. aeruginosa strain investigated, treatment of infected larvae with PAβN (at 200 
100mg/kg) in combination with levofloxacin or piperacillin (both at strain specific doses) did not confer any 201 
therapeutic benefit over antibiotic treatment alone (P≥0.05) (data not shown).  202 
Pilot studies revealed that combinations of trimethoprim or sertraline with levofloxacin gave the most 203 
promising results so these were selected for detailed study. A single treatment with combinations of 204 
levofloxacin + trimethoprim or levofloxacin + sertraline resulted in a small increase in survival of larvae 205 
infected with the parent strain (PAM1020) after 96 h compared to those treated with PBS or the constituent 206 
monotherapies but conferred no additional therapeutic benefit over the monotherapies with the strain over-207 
expressing mexAB-oprM (PAM1032) (data not shown). The experiment was repeated using triple-dosing of 208 
each treatment 2, 4 and 6 h p.i (Figure 2). Triple doses of levofloxacin + trimethoprim or levofloxacin + 209 
sertraline resulted in significant increases in survival compared to triple doses of any of the monotherapies 210 
over the 96 h duration of the experiment. Notably, the enhanced therapeutic benefit conferred by treatment 211 
with the combinations was observed for infections with either the parent (PAM1020) or the strain over-212 
expressing mexAB-oprM (PAM1032). This is in contrast to the results seen in vitro where neither of the 213 
combinations was observed to be synergistic when tested against the mexAB-oprM over-expressing strain.  214 
Comparison of the effect of triple doses of levofloxacin + trimethoprim or levofloxacin + sertraline with the 215 
constituent monotherapies on the larval burden of the parent strain (PAM 1020) is shown in Figure 3. Larval 216 
burden following three doses of PBS increased from below the level of detection (≤ 2 log10cfu/mL) 5 h post-217 
infection to greater than 9 log10cfu/mL after 24 h at 37ºC. Treatment with three doses of trimethoprim 218 
(100mg/kg) or sertraline (100 mg/kg) also resulted in rapid proliferation of bacteria after 24 h. The rapid 219 
growth in bacterial numbers seen 24 h after triple-dose treatment with PBS, trimethoprim or sertraline 220 
 correlated with death of the larval population (Figure 2). Treatment with three doses of levofloxacin (1 221 
mg/kg) did retard bacterial growth after 24 h but this inhibition was abolished after 48 h as the bacterial 222 
population increased to approximately 10 log10cfu/mL and the larval population died (Figure 2). Treatment 223 
with triple doses of levofloxacin + trimethoprim or levofloxacin + sertraline completely eradicated bacterial 224 
growth in infected larvae with detected numbers remaining below the level of detection (≤ 2 log10cfu/mL) in 225 
most cases and this was reflected in the high levels of larval survival observed (Figure 2).  In summary, the 226 
therapeutic benefit arising from treatment with efflux-pump inhibitor/antibiotic combination treatments 227 
correlates with reduced larval burden of infecting P. aeruginosa. 228 
To determine if the enhanced therapeutic benefit arising from treatment with efflux-pump inhibitor/antibiotic 229 
combination treatments was also evident versus an infection by a different MDR strain an experiment was 230 
performed using P. aeruginosa NCTC1343712 (Table 1). Importantly, treatment with triple doses of 231 
levofloxacin + trimethoprim or levofloxacin + sertraline again resulted in significant increases in survival of 232 
larvae infected with this strain compared to treatment with any of the constituent monotherapies over the 96 233 
h duration of the experiment (Supplementary Figure 2). 234 
 235 
Discussion 236 
Strains of P. aeruginosa harbouring mutations that result in the over-expression of efflux-pumps are 237 
frequently isolated in the clinical setting. Invariably, these strains result in antibiotic treatment complications, 238 
or failure, due to their antibiotic-resistant phenotype.18,19 This study has demonstrated that P. aeruginosa 239 
strains that over-express efflux-pumps also result in the failure of antibiotic treatment in G. mellonella 240 
larvae. The similarity between the antibiotic-resistant phenotypes of strains in the invertebrate infection 241 
model and human patients shows that G. mellonella larvae represent a highly effective tool to develop and 242 
evaluate novel treatment options to target clinical MDR strains of P. aeruginosa.   243 
Piddock et al.9 and Bohnert et al.10 presented evidence from in vitro studies that trimethoprim and sertraline 244 
both possessed EPI-like properties. Trimethoprim has been shown to be a substrate of the Mex pumps, in 245 
particular MexAB-OprM20, and this explains the high levels of resistance measured in the over-expressing 246 
strains and the apparent susceptibility of the strain with all three Mex pumps deleted in this work 247 
(Supplementary Table 1). Data shown here (Table 3), reveals that combinations of antibiotics with 248 
 trimethoprim or sertraline that were synergistic versus the P. aeruginosa parent strain did not show synergy 249 
when applied to the strain with three efflux-pumps deleted supporting the previous conclusion that the two 250 
drugs do have EPI activity.  251 
The present work has presented in vivo evidence that antibiotic and trimethoprim (or sertraline) 252 
combinations represent a potential treatment option for P. aeruginosa infections. Administration of 253 
combinations of trimethoprim or sertraline with levofloxacin conferred significant therapeutic benefit in vivo 254 
to infected G. mellonella larvae compared to those treated with the individual monotherapies. Importantly, 255 
the enhanced therapeutic effect of these combinations in vivo was demonstrated against a MDR strain of P. 256 
aeruginosa that over-expresses the MexAB-OprM efflux-pump. In terms of clinical relevance, the doses of 257 
levofloxacin (1-5 mg/kg) employed in this study are comparable to those used in humans – approximately 8 258 
mg/kg.13 For human therapy, trimethoprim is usually administered in combination with sulfamethoxazole 259 
with trimethoprim at 20 mg/kg.21 This is lower than the dose of trimethoprim (100 mg/kg) in the successful 260 
combination reported here and further studies will be needed to determine if it is feasible to employ this 261 
higher dose of trimethoprim clinically. Furthermore, Bohnert et al.10 have already stated that sertraline is 262 
unlikely to be successful in combination treatments as the peak plasma levels attained are below the 263 
concentrations that are required to inhibit efflux.  264 
It is notable that combinations of both trimethoprim and sertraline with levofloxacin were not synergistic 265 
versus the strain over-expressing the MexAB-OprM efflux-pump in vitro but resulted in significant 266 
therapeutic benefit when tested in vivo. Similarly, combinations of PAβN with levofloxacin were synergistic 267 
in vitro but conferred no therapeutic advantage over monotherapies when administered in vivo (data not 268 
shown). These discrepancies between results obtained in vitro with those observed in vivo concur with 269 
previous observations evaluating the efficacy of antibiotic only combination therapies carried out in the 270 
corresponding author’s lab.16 In fact, there are examples in the literature where synergy between two 271 
antibiotics observed in vitro does not translate into enhanced therapeutic benefit in patients.22 The 272 
implication of this is that by employing traditional in vitro methods to screen for effective combination 273 
treatments (or novel antimicrobials per se) researchers could actually be discarding potential treatments 274 
that are efficacious in vivo. Thus, screening in vivo using G. mellonella may be a better predictor of the 275 
efficacy of novel treatments in patients than in vitro assays. To evaluate this possibility, studies are needed 276 
urgently that compare the relative efficacy of established and novel treatments on infections in G. 277 
mellonella with murine models, and ultimately in human patients, to determine how relevant to the 278 
 outcomes of human infections results obtained with G. mellonella actually are. With P. aeruginosa, a 279 
positive correlation between the degrees of pathogenicity of a range of mutant strains was demonstrated in 280 
G. mellonella and mice23 but there are few published studies comparing antibiotic efficacy in G. mellonella 281 
with murine, or human, infections. Clearly, any effects identified in G. mellonella may not be relevant to 282 
other mammalian infection models or humans. In addition to the obvious differences in the immune system 283 
of invertebrates and mammals, the efficacy of some antimicrobial drugs versus infected G. mellonella has 284 
been attributed not just to direct inhibition of the pathogen but also to activation, or priming, of the larval 285 
innate immune response.24 Additional experimentation will be required to determine if the efficacy of the 286 
combination treatments reported here is relevant in mammals. 287 
In summary, antibiotic-resistant strains of P. aeruginosa that over-express drug efflux-pumps and result in 288 
treatment failure in human patients also result in the failure of antibiotic treatment in G. mellonella larvae. 289 
Furthermore, combination treatments consisting of the putative EPIs, trimethoprim and sertraline, with 290 
levofloxacin were significantly more efficacious than the individual monotherapies. The enhanced efficacy 291 
of these combinations versus infected G. mellonella was evident against a MDR strain of P. aeruginosa that 292 
over-expresses the MexAB-OprM efflux-pump, confirming that combinations of antibiotics with EPIs are a 293 
potential treatment option for real infections with MDR P. aeruginosa. This study has also highlighted 294 
discrepancies in results obtained from in vitro and in vivo antimicrobial testing that could mean false 295 
positives are inadvertently selected and novel treatment options missed. Together, these findings further 296 
demonstrate the utility of using G. mellonella to develop and evaluate novel treatment options to target 297 
clinical MDR strains of P. aeruginosa.   298 
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 Legends for Figures 378 
Figure 1. Effect of antibiotic treatment on survival of G. mellonella larvae infected with P. aeruginosa 379 
PAM1020, 1032, 1033, 1034 and 1626. Larvae were infected with 2.5 x 103 cfu/mL of each strain. A single 380 
dose of antibiotic was administered 2 h p.i : LVX at 0.2, 1 or 5 mg/kg; PIP at 10, 25 or 100 mg/kg; and MER 381 
at 0.1, 0.25 or 0.5 mg/kg. Larvae were incubated at 37°C for 96 h and survival recorded every 24 h. The 382 
uninfected group represents larvae sham-infected with sterile PBS and treated with sterile PBS. The PBS 383 
group represents larvae infected with P. aeruginosa and treated with sterile PBS. For clarity, on each graph 384 
only data for PAM1020 is shown for the unmanipulated, uninfected and PBS control groups as the data 385 
was identical for each strain (P>0.05). * indicates a group with significantly enhanced or reduced survival in 386 
comparison to the other strains (P<0.05, log-rank test). n=30 (pooled from duplicate experiments). 387 
 388 
Figure 2. Effect of treatment with combinations of LVX + TMP and LVX + SER on survival of G. mellonella 389 
larvae infected with P. aeruginosa PAM 1020 or PAM 1032. All larvae were inoculated with 2.5x103 cfu/mL 390 
P. aeruginosa and treated with each drug individually or in combination with three doses at 2, 4 and 6 h p.i. 391 
Treatments consisted of PBS, LVX, TMP (100 mg/kg) or SER (100 mg/kg) alone, or combinations of LVX 392 
with TMP (100 mg/kg) or SER (100 mg/kg). The LVX doses used were strain and dose-dependent and the 393 
dose is indicated on the graph (mg/kg). Larvae were incubated at 37°C for 96 h and survival recorded every 394 
24 h. Data for groups of unmanipulated larvae is omitted as it was identical to the uninfected groups sham-395 
infected with sterile PBS and treated with sterile PBS. * indicates a combination treatment group with 396 
significantly enhanced survival compared to any of the constituent monotherapies (P<0.05, log-rank test 397 
with Holm correction for multiple comparisons). n=30 (pooled from duplicate experiments). 398 
 399 
Figure 3. Effect of treatment with combinations of LVX + TRIM and LVX + SER on larval burden of P. 400 
aeruginosa PAM1020.  All larvae were inoculated with 2.5x103 cfu/mL P. aeruginosa and treated with three 401 
doses of each individual drug or combinations at 2, 4 and 6 h p.i. Treatments consisted of PBS, LVX (1 402 
mg/kg), TMP (100 mg/kg) or SER (100 mg/kg) alone, or combinations of LVX (1 mg/kg) with TMP (100 403 
mg/kg) or SER (100 mg/kg). Larvae were incubated at 37°C for 96 h and the burden of P. aeruginosa 404 
determined from 5 individual larvae every 24 h. For clarity, data for treatment with PBS, TMP and SER 405 
 alone is only shown for 24 h because the data obtained for subsequent data points closely followed that 406 
shown for LVX (1 mg/kg) treatment. # indicates a significant difference in larval burden between groups 407 
treated with the combination of LVX and TMP (or SER) compared to the constituent monotherapies; n=5 408 
(P<0.05, Mann-Whitney U test). The black bar represents the median value of larval burden per group. 409 
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 432 
 Table 1. Pseudomonas aeruginosa strains used in this study.  433 
 434 
Strain Genotype Status of efflux pumps Reference 
PAM1020 PAO1 prototroph Wild-type control 11 
PAM1626 ΔmexAB-oprM::Cm; ΔmexCD-
oprJ::Gm; ΔmexEF-oprN::ΩHg  
mexAB-oprM; mexCD-oprJ; and 
mexEF-oprN deleted 
11 
PAM1032 nalB - type mutation mexAB-oprM over-expressed 11 
PAM1033 nfxB - type mutation mexCD-oprJ over-expressed 11 
PAM1034 nfxC - type mutation mexEF-oprN over-expressed 11 
NCTC13437 Clinical isolate producing VEB-1 and 
VIM-10 β-lactamases 
Resistant to fluoroquinolones 
and aminoglycosides by 
unknown mechanisms 
12 
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 Table 2. MICs of six antibiotics against Pseudomonas aeruginosa PAM1020, 1032, 1033, 1034 and 1626 459 
determined in Mueller-Hinton broth after incubation at 37°C for 24 h. Each experiment was performed at 460 
least in triplicate. 461 
 462 
 463 
Strain Genotypea MIC (mg/L) 
CFD PIP MER LVX AMK CST 
PAM1020 Parent 1 4-8 0.5-1 0.5 2 1-4 
PAM1032 nalB 2-4 16-32 4 2 0.5-1 0.25-1 
PAM1033 nfxB 0.5-1 2-4 0.25-1 4 0.25-1 0.5-1 
PAM1034 nfxC 1 2 0.25-0.5 4 0.25-1 0.125-0.5 
PAM1626 Δmex 0.5 0.25-0.5 0.0625-0.125 0.03125 1 1 
 464 
aWT, isogenic parent; nalB, overexpressing MexAB-OprM; nfxB, over-expressing MexCD-OprJ; nfxC, 465 
overexpressing MexEF-OprN; Δmex, triple deletion ΔmexAB-oprM::Cm; ΔmexCD-oprJ::Gm; ΔmexEF-466 
oprN::ΩHg. 467 
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 Table 3. MICs of three antibiotics in the absence and presence of three putative EPIs against 486 
Pseudomonas aeruginosa PAM1020, 1032 and 1626. Antibiotics were double diluted in Mueller-Hinton 487 
broth and EPI added to each well individually, plates were incubated for 24 h at 37°C. Each experiment 488 
was completed at least in duplicate. 489 
 490 
Strain Drug Drug MIC (mg/L) with  FIC index b 
No EPI TMP a SER a PAβN a  Drug+TMP Drug+SER Drug+PAβN 
PAM1020 LVX 0.5 >0.004 0.125 0.156  0.008 0.252 0.031 
 PIP 4-8 1 1-2 1-2  0.266 0.531 0.266 
 MER 0.5-1 0.5 >0.004 0.25  0.508 0.008 0.502 
PAM1032 LVX 2 2 2 0.031  1 1 0.016 
 PIP 16-32 32 16 4  2 0.75 0.156 
 MER 4 4 2 0.25  1 0.531 0.065 
PAM1626 LVX 0.031 0.031 0.016 0.016  1 0.501 0.500 
 PIP 0.25-0.5 0.5 0.25 0.5  2.25 0.516 1 
 MER 0.062-
0.125 
0.125 0.062 0.125  1.1 1 1 
 491 
a The concentration of putative EPI added to each well reflected the previously characterised EPI MICs 492 
(Table 2) and were selected to be lower than the EPI MIC for each strain. PAM1020:  TMP (50 mg/L), SER 493 
(50 mg/L), PAβN (100 mg/L); PAM1032 TMP (100 mg/L), SER (50 mg/L), PAβN (100 mg/L); PAM1626 494 
TMP (0.5 mg/L), SER (5 mg/L), PAβN (10 mg/L).  495 
 496 
b Fractional inhibitory concentration index (FIC index) where synergistic (≤ 0.5), non-synergistic (> 0.5 – 497 
≤4.0) and antagonistic (>4). Where actual MICs were not detected for some EPIs, the highest value tested 498 
was used in the FICI calculation to provide a conservative estimate of the FICI value. Bold text indicates 499 
synergy. 500 
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